Edwards Lifesciences Corporation (EW) shows continued stock price volatility. The firm saw recent selling activity by its VP and various investment advisors, with shares also taking a dip to $79.34. Both Nisa Investment Advisors and VP Donald Bobo Jr offloaded considerable shares, with Nordea Investment Management AB, AIA Group, and Cinctive Capital Management making similar moves. However, various institutions including J. Safra Sarasin Holding AG, Allspring Global Investments, Assenagon Asset Management, and Bank of Montreal increased their stakes in EW. EW performance has been generally positive though, with recent analyst upgrades signalling a renewed growth cycle and superior performance compared to the S&P 500. The growth story for the company is apparently shifting as they tighten their expectations through 2026. The firm's Q4 earnings triggered a fall in the stock, however, they managed to exceed revenue predictions despite missing EPS estimates. Analysts keep a close eye on upcoming earnings reports, gauging the future outcomes. They project robust growth driven particularly by the TAVR market and renewal of growth cycles, despite concerns over valuation and high P/E. Finally, amidst these varying outlooks, EW holds an ambitious plan to reach 2 million underserved heart patients by 2030.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Fri, 03 Apr 2026 09:01:49 GMT -
Rating 1
- Innovation 2
- Information 4
- Rumor 3
